Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    Patient safety
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    September 28, 2022
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    Radiation therapy
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    August 19, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Multiple myeloma

    FDA Approves Teclistamab-Cqyv for Relapsed or Refractory Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Teclistamab-Cqyv for Relapsed or Refractory Multiple Myeloma

    On October 25, 2022, the U.S. Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli®), the first bispecific B-cell maturation antigen–directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

     

    October 26, 2022
    FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

    On February 28, 2022, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti™) for adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody. Ciltacabtagene autoleucel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy.

    March 18, 2022
    Nursing Considerations for Isatuximab Combination Therapy
    Combination therapy

    Nursing Considerations for Isatuximab Combination Therapy

    Clinicians often use combination cancer therapies to overcome treatment resistance, and one of the newest options for certain patients with multiple myeloma is isatuximab, a monoclonal antibody (mAb). Approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received at least two prior therapies, isatuximab prolonged progression-free survival by nearly six months and produced an overall response rate of more than 60% in the drug’s clinical trials.

    February 08, 2022
    FDA Approves Daratumumab Hyaluronidase-Fihj, Carfilzomib, Dexamethasone for Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Daratumumab Hyaluronidase-Fihj, Carfilzomib, Dexamethasone for Multiple Myeloma

    On November 30, 2021, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro™), carfilzomib (Kyprolis®), and dexamethasone for adult patients with relapsed or refractory multiple myeloma who received one to three prior lines of therapy.

    December 01, 2021
    Oncology Drug Reference Sheet: Belantamab Mafodotin-Blmf
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Belantamab Mafodotin-Blmf

    A first-of-its-kind antibody-drug conjugate for multiple myeloma, belantamab mafodotin-blmf (Blenrep) received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2020. The approval was based on clinical trial findings that demonstrated a 31% overall response rate that lasted at least six months in 73% of responders.

    October 26, 2021
    ONS Bridge

    New Multiple Myeloma Treatments Present New Challenges in Side Effect Management

    New strategies are emerging to manage the complex side effects and adverse events from multiple myeloma (MM) therapies, Lorraine Mack, APN/MSN CNL, OCN®, AOCNS®, and Dodi Georges, MSN, CWON, OCN®, both from Northwestern Medicine, said during a session held September 14, 2021, at the ONS BridgeTM virtual conference. They shared best practices for nursing interventions for patients undergoing new treatment options.

    September 14, 2021
    FDA Approves Isatuximab-Irfc for Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Isatuximab-Irfc for Multiple Myeloma

    On March 31, 2021, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. 

    April 01, 2021
    FDA Approves Idecabtagene Vicleucel as the First Cell-Based Gene Therapy for Adult Patients With Multiple Myeloma
    Clinical practice

    FDA Approves Idecabtagene Vicleucel as the First Cell-Based Gene Therapy for Adult Patients With Multiple Myeloma

    On March 27, 2021, the U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (Abecma), for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma. 

    March 30, 2021
    FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
    Clinical practice

    FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma

    On February 26, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (Pepaxto®) in combination with dexamethasone for adults with relapsed or refractory multiple myeloma who received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38–directed monoclonal antibody.

    March 01, 2021
    FDA Approves Selinexor for Relapsed or Refectory Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Selinexor for Relapsed or Refectory Multiple Myeloma

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved selinexor (Xpovio®) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refectory multiple myeloma who have received at least one prior therapy. 

    December 21, 2020
    Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations
    Clinical practice

    Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations

    Multiple myeloma is a plasma cell neoplasm and the second most common hematologic malignancy in the United States, although overall incidence rates are relatively low at approximately 32,000 annually. The overall five-year survival rate is 52%, and most people are diagnosed with the disease in later stages.

    June 09, 2020
    FDA Approves Isatuximab-irfc for Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Isatuximab-irfc for Multiple Myeloma

    On March 2, 2020, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa®) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

    March 02, 2020
    FDA Approves Daratumumab for Transplant-Eligible Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Daratumumab for Transplant-Eligible Multiple Myeloma

    On September 26, 2019, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex®) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant.

    September 26, 2019
    Ancestry Analysis Identifies Genetic Cause for Increased Multiple Myelmoma in African Americans
    Research

    Ancestry Analysis Identifies Genetic Cause for Increased Multiple Myeloma in African Americans

    Three cytogenetic subtypes are particularly responsible for the increased incidence of multiple myeloma in people of African descent, according to the results of a study published in Blood Cancer Journal.

    March 20, 2019
    American Society of Hematology Annual Meeting

    Genetics Plays a Role in Treatment Response for Relapsed or Refractory Multiple Myeloma

    No molecular-informed personalized therapies are currently available for patients with relapsed/refractory multiple myeloma (MM); however, cytogenetics and next-generation sequencing (NGS) can identify molecular abnormalities to provide guidance for more targeted therapy. Tarek Assi, MD, of Gustave Roussy Cancer Campus in Villejuif, France, discussed his research team’s findings that tumor genotyping is associated with higher response rates and prolonged duration of therapy at the ASH Annual Meeting on December 1, 2018.

    December 01, 2018
    Infection Linked to Early Mortality in Post-ASCT Multiple Myeloma
    Multiple myeloma

    Infection Linked to Early Mortality in Post-ASCT Multiple Myeloma

    Patients with multiple myeloma are at increased risk for early death from infection after high-dose therapy and autologous stem cell transplantation (ASCT), according to the results of a study published in the American Journal of Hematology.

    December 13, 2017
    American Society of Hematology Annual Meeting

    Multiple Myeloma Survivors Still Experience Symptoms and Psychological Concerns

    Survival from multiple myeloma (MM) has improved, and more attention is required for symptom burden and psychological impact in the long-term management of this disease. Researchers assessed the incidence of self-reported pain, depression, financial and family burden, and impairment of performance status, as well as determined the correlation of total distress with survival. Joshua R. Richter, MD, at the John Theurer Cancer Center in Hackensack, NJ, discussed the findings at the ASH Annual Meeting.

    December 11, 2017
    American Society of Hematology Annual Meeting

    Patients With MM Receiving PIs Need Herpes Zoster Prophylaxis

    Patients with multiple myeloma (MM) who receive proteasome inhibitors (PIs) are at an increased risk for herpes zoster infection, and National Comprehensive Cancer Network guidelines recommend antiviral prophylaxis for these patients. Researchers examined the use of and adherence to antiviral agents in this patient population. Siyang Leng, MD, at Columbia University Medical Center in Sunnyside, New York, discussed the findings at the ASH Annual Meeting.

    December 09, 2017
    Manage Oncologic Emergencies With Multiple Myeloma
    Multiple myeloma

    Manage Oncologic Emergencies With Multiple Myeloma

    As new therapies come to market, patients with multiple myeloma have more treatment options that are improving outcomes and extending overall survival. However, the most effective options involve multidrug combinations and continuous maintenance therapy, which can result in cumulative toxicities and the potential for oncologic emergencies.

    November 07, 2017
    Bortezomib May Improve Outcomes in Multiple Myeloma
    Multiple myeloma

    Bortezomib May Improve Outcomes in Multiple Myeloma

    Adding bortezomib to combination therapy with lenalidomide and dexamethasone may improve progression-free and overall survival in patients with newly diagnosed multiple myeloma. The study findings were published in Lancet.

    April 12, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma

    On February 22, 2017, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid®, Celgene Corp.) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.

    February 23, 2017

    Statin Use May Improve Overall Survival From Multiple Myeloma

    A new study has found that use of statin medications in patients with multiple myeloma was associated with a decreased risk of all-cause and cancer-specific mortality. The findings were published in the Journal of Clinical Oncology.
    January 10, 2017
    Multiple myeloma

    New Treatments and Insights in Multiple Myeloma

    An interview with Beth Faiman, PhD, CNP, and Kimberly Noonan, NP

    June 03, 2016
    Oncology patient with multiple myeloma
    Cancer treatments

    Multiple Myeloma Is Incurable but Treatable

    This content was developed by ONS, Beth Faiman, PhD, CNP, and Kimberly Noonan, NP, and is sponsored by Amgen. Faiman and Noonan received no payment for their participation.

    April 05, 2016
    Combination therapy

    FDA Approves Carfilzomib in Combination With Lenalidomide and Dexamethasone for Treatment of Relapsed Multiple Myeloma

    On July 24, 2015, the U.S. Food and Drug Administration approved carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc., an Amgen subsidiary) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
    July 24, 2015
    Side effects of hypercalcemia
    Clinical practice

    The Case of the Mind-Altering Mineral

    Hal is a 73-year-old patient with refractory multiple myeloma. Florence, his wife, calls the hematologist’s office and asks to speak with the triage nurse. She says she is worried about her husband and that “he’s just not himself.” What would you do?
    November 19, 2013
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲